CTOs on the Move

Pacific Biomarkers

www.pacbio.com

 
Pacific Biomarkers is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pacbio.com
  • 220 W Harrison St
    Seattle, WA USA 98119
  • Phone: 206.298.0068

Executives

Name Title Contact Details

Similar Companies

Germiphene Corporation

Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

4 dry skin natural products

4 dry skin natural products is a Nashville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sagimet

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.

Greater Cincinnati Behavioral Health Services

Cincinnati Comprehensive Mental Health Agency helping people through many services and a staff of more than 500 highly skilled professionals.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.